The pulmonary arterial hypertension market size is expected to see strong growth in the next few years. It will grow to $11.99 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to adoption of novel therapies for pulmonary arterial hypertension, increased focus on early detection and diagnosis, growing pipeline of pah drugs and therapies, integration of precision medicine in pah treatment, expansion of healthcare infrastructure in emerging markets. Major trends in the forecast period include advancements in medical imaging and diagnostic technologies, collaboration and partnerships for drug development, patient-centric approaches in pulmonary arterial hypertension management, increased use of combination therapy.
To access more details regarding this report, visit the link:
Segmentation & Regional Insights
The pulmonary arterial hypertension market covered in this report is segmented –
1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators
2) By Route of Administration: Oral, Intravenous/ subcutaneous, Inhalational
3) By Distribution channel: Retail, Online
North America was the largest region in the pulmonary arterial hypertension market in 2023. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=5954&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of pulmonary arterial hypertension (PAH) disease is contributing to the growth of the pulmonary arterial hypertension market. The increasing prevalence of PAH diseases and the related hospitalization of patients for treatment is expected to boost the demand for relevant drugs during the forecast period. According to a study published by the National Organization for Rare Disorders, Inc., new cases of PAH are estimated to occur in one to two individuals per million each year in the USA, which equates to 500–1000 new cases each year, and Europe is expected to have similar incidence rates.
Key Industry Players
Major companies operating in the pulmonary arterial hypertension market report are United Therapeutics Corporation, Acceleron Pharma Inc., Actelion Pharmaceuticals US Inc., Bayer AG, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Liquidia Technologies Inc., Lupin Pharmaceuticals Inc., Natco Pharma Ltd., Pfizer Inc., Sandoz AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceutical USA Inc., Allegheny Health Network, Cedars-Sinai Medical Center, Cleveland Clinic, Houston Methodist Hospital, Johns Hopkins Medicine, Massachusetts General Hospital, Mayo Clinic, MedStar Heart & Vascular Institute, National Jewish Health, NewYork-Presbyterian Hospital, Ochsner Medical Center, Royal Brompton & Harefield NHS Foundation Trust, Rush University Medical Center, Stanford Health Care, Swedish Medical Center, Temple University Hospital, University of California Health.
The pulmonary arterial hypertension market report table of contents includes:
1. Executive Summary
2. Pulmonary Arterial Hypertension Market Characteristics
3. Pulmonary Arterial Hypertension Market Trends And Strategies
4. Pulmonary Arterial Hypertension Market - Macro Economic Scenario
5. Global Pulmonary Arterial Hypertension Market Size and Growth
.................
31. Global Pulmonary Arterial Hypertension Market Competitive Benchmarking
32. Global Pulmonary Arterial Hypertension Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Pulmonary Arterial Hypertension Market
34. Pulmonary Arterial Hypertension Market Future Outlook and Potential Analysis
35. Appendix
Explore the trending research reports from TBRC:
https://goodprnews.com/farm-animal-healthcare-global-market-size/
https://goodprnews.com/fraud-hunters-global-market-size/
https://goodprnews.com/hand-held-chemical-and-metal-size/
https://topprnews.com/farm-animal-healthcare-global-market-share/
https://topprnews.com/fraud-hunters-global-market-share/
https://topprnews.com/hand-held-chemical-and-metal-share/
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
The global pulmonary arterial hypertension (PAH) market size was valued at USD 5.0 billion in 2015 and is anticipated to reach USD 8.7 billion by 2025.
PAH occurs when the pulmonary arteries thicken or grow rigid.
These drugs have superiority over existing therapy options with respect to the therapeutic efficacy, route of administration, and side-effects.Download Free Sample Report @ https://www.millioninsights.com/industry-reports/pulmonary-arterial-hypertension-pah-market/request-sampleA new drug called Uptravi (selexipag), which is a selective IP prostacyclin receptor agonist, is expected to be launched in 2016 and is likely to drive growth of the prostacyclin and prostacyclin analogs market.
In the U.S., the Orphan Drug Act (ODA) encourages pharmaceutical industries to develop orphan drugs by offering benefits such as tax credits, research grants, and orphan drug exclusivity of seven years.
Transplantation- Lung or heart-lung transplant might be an option especially for younger people who have idiopathic pulmonary arterial hypertension.Geographically, PAH market is segmented into North America, Europe, Asia Pacific, Latin America, MEA, and Rest of the World.
North America held the maximum share of market for PAH in terms of revenue in 2013, which is then followed by Europe.
The ‘Pulmonary Arterial Hypertension (PAH)- Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of PAH in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
Also the Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Pulmonary Arterial Hypertension (PAH) from 2016 to 2027 segmented by seven major markets.Complete report on Global Pulmonary Arterial Hypertension (PAH) Market Size, Trends And Forecast Report 2014 – 2025 Enquire more@ https://franknraf.com/reports/global-pulmonary-arterial-hypertension-pah-market-size-trends-and-forecast-report-2014-2025/The Report research analysis also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered The United States EU5 (Germany, France, Italy, Spain and the United Kingdom) Japan Study Period: 2016-2027 Pulmonary Arterial Hypertension (PAH) - Disease Understanding and Treatment Algorithm.Get Sample copy of the report@ https://franknraf.com/sample-report/?rpt_id=6169The Pulmonary Arterial Hypertension (PAH) market report gives the thorough understanding of the Pulmonary Arterial Hypertension (PAH) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends.
The research analysis also provides treatment algorithms and treatment guidelines for Pulmonary Arterial Hypertension (PAH) in the US, Europe, and Japan.
Pulmonary Arterial Hypertension (PAH) Epidemiology The Pulmonary Arterial Hypertension (PAH) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries.
Also it helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.Pulmonary Arterial Hypertension (PAH) Drug Chapters This segment of the Pulmonary Arterial Hypertension (PAH) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
Latest Report Published on Pulmonary Arterial Hypertension Pah Drugs Market - Industry Segment by growth, Applications, by Type, Regional Outlook, Demand, Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts – 2027.” This Pulmonary Arterial Hypertension Pah Drugs Market is Segmented in two kinds based on the sort of materials and end-clients.
It has worldwide market canvassed in every one of the areas, running to that crucial market, key patterns and division investigation are covered all through Pulmonary Arterial Hypertension Pah Drugs market report.Free PDF Brochure @ https://www.crystalmarketresearch.com/report-sample/HC018133As far as the competitive scale is concerned, the report also enlists the information regarding the Pulmonary Arterial Hypertension Pah Drugs market growth tactics undertaken by the industry players, such as expansion strategies and mergers and acquisitions.
This report discusses the key drivers influencing Pulmonary Arterial Hypertension Pah Drugs market growth, opportunities, the challenges and the risks faced by key players and the market.Report Scope:The study includes the profiles of key players in the Pulmonary Arterial Hypertension Pah Drugs market with a significant global and regional presence.
The Pulmonary Arterial Hypertension Pah Drugs market competition by Top Manufacturers Covers:ActelionPfizerGilead SciencesBayerUnited TherapeuticsArenaGlaxoSmithKlinePulmonary Arterial Hypertension (PAH) Drugs MarketContinue...Key Businesses Segmentation:Pulmonary Arterial Hypertension (PAH) Drugs Market , By Type, Estimates and Forecast, 2014-2025 ($Million)Prostacyclin and Prostacyclin AnalogsERASGC StimulatorsPDE-5Pulmonary Arterial Hypertension (PAH) Drugs Market , By Application, Estimates and Forecast, 2014-2025 ($Million)ClinicHospitalPulmonary Arterial Hypertension (PAH) Drugs MarketThe market study by Region:North America Region (U.S, Canada, Mexico);Europe Region (Germany, UK, France, Russia, Italy, Rest of Europe);Asia-Pacific Region (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific);South America Region (Brazil, Argentina, Columbia, Rest of South America);The Middle East and Africa Region (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA);For better understanding - Feel Free to inquire more about 'Pulmonary Arterial Hypertension Pah Drugs market' @ https://www.crystalmarketresearch.com/send-an-enquiry/HC018133Following are Chapters to display the Global Pulmonary Arterial Hypertension Pah Drugs market:-Section 1: Represents Definition, Specifications, and Classification, Applications of Pulmonary Arterial Hypertension Pah Drugs, Market Segment by RegionsSection 2: To break down the Suppliers and Raw Material, Pulmonary Arterial Hypertension Pah Drugs Manufacturing Process, Industry Chain Structure, Manufacturing Cost StructureDelivery Timeline 24-48 hoursContacts Us:Sherry | APAC Marketing Division: Level 23-1, Premier Suite, Mont Kiara, 50480 Kuala Lumpur, MalaysiaE-mail: [email protected] | Ph: +1-888-213-4282
